Phio Pharmaceuticals (PHIO) Competitors $2.38 0.00 (0.00%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$2.36 -0.02 (-1.05%) As of 07/16/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHIO vs. ANVS, EYEN, MDCX, NBRV, APLT, PLUR, PRLD, MURA, ATNM, and SCLXShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Annovis Bio (ANVS), Eyenovia (EYEN), Medicus Pharma (MDCX), Nabriva Therapeutics (NBRV), Applied Therapeutics (APLT), Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. Its Competitors Annovis Bio Eyenovia Medicus Pharma Nabriva Therapeutics Applied Therapeutics Pluri Prelude Therapeutics Mural Oncology Actinium Pharmaceuticals Scilex Annovis Bio (NYSE:ANVS) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Do insiders & institutionals hold more shares of ANVS or PHIO? 15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings and valuation, ANVS or PHIO? Annovis Bio is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.16-1.29Phio PharmaceuticalsN/AN/A-$7.15M-$6.42-0.37 Does the media refer more to ANVS or PHIO? In the previous week, Phio Pharmaceuticals had 2 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Phio Pharmaceuticals and 0 mentions for Annovis Bio. Phio Pharmaceuticals' average media sentiment score of 0.93 beat Annovis Bio's score of 0.00 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Annovis Bio Neutral Phio Pharmaceuticals Positive Which has more risk & volatility, ANVS or PHIO? Annovis Bio has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Do analysts rate ANVS or PHIO? Annovis Bio presently has a consensus price target of $18.00, suggesting a potential upside of 545.86%. Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 488.24%. Given Annovis Bio's higher probable upside, equities analysts clearly believe Annovis Bio is more favorable than Phio Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ANVS or PHIO more profitable? Phio Pharmaceuticals' return on equity of -105.65% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -300.56% -193.50% Phio Pharmaceuticals N/A -105.65%-89.19% SummaryPhio Pharmaceuticals beats Annovis Bio on 7 of the 13 factors compared between the two stocks. Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.42M$2.41B$5.51B$9.31BDividend YieldN/A1.79%4.25%4.08%P/E Ratio-0.379.1828.1519.68Price / SalesN/A755.11439.01100.25Price / CashN/A160.6835.5357.53Price / Book3.454.698.235.67Net Income-$7.15M$30.99M$3.23B$257.51M7 Day Performance-2.46%-0.20%-0.56%-0.16%1 Month Performance-0.83%8.67%6.67%9.89%1 Year Performance-49.58%-4.17%27.00%15.08% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals2.5558 of 5 stars$2.38flat$14.00+488.2%-48.4%$11.42MN/A-0.3710News CoverageANVSAnnovis Bio1.5589 of 5 stars$2.39+1.3%$18.00+653.1%-77.6%$45.99MN/A-1.113EYENEyenoviaN/A$15.96+51.1%$2.00-87.5%N/A$45.97M$60K-0.2740High Trading VolumeMDCXMedicus Pharma2.1896 of 5 stars$3.40+0.6%$23.50+591.2%N/A$45.88MN/A-2.93N/ANews CoverageHigh Trading VolumeNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070APLTApplied Therapeutics4.5443 of 5 stars$0.34+4.9%$6.10+1,717.6%-92.2%$45.30M$460K-0.7830Positive NewsGap UpPLURPluri3.2867 of 5 stars$5.79+0.2%$12.00+107.3%-13.7%$45.28M$330K-1.05150Positive NewsGap DownPRLDPrelude Therapeutics3.6977 of 5 stars$0.81+1.6%$4.50+457.8%-86.8%$44.82M$7M-0.48120Positive NewsMURAMural Oncology3.4332 of 5 stars$2.48-3.9%$12.00+383.9%-28.4%$44.55MN/A-0.32119ATNMActinium Pharmaceuticals2.807 of 5 stars$1.42-1.4%$4.00+181.7%N/A$44.30MN/A-1.0230Positive NewsSCLXScilex2.5531 of 5 stars$6.25-1.7%$455.00+7,180.0%-89.8%$44.21M$56.59M-0.2280Positive News Related Companies and Tools Related Companies ANVS Competitors EYEN Competitors MDCX Competitors NBRV Competitors APLT Competitors PLUR Competitors PRLD Competitors MURA Competitors ATNM Competitors SCLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHIO) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHIO Stock Alerts